Zai Lab Limited (ZLAB, Financial) has received a significant boost as China's National Medical Products Administration has accepted its supplemental new drug application for repotrectinib. This drug is aimed at treating adult patients with solid tumors that contain a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
The application specifically targets patients whose conditions are either locally advanced or metastatic. It is also applicable for cases where surgical options might lead to severe health consequences. This treatment is intended for individuals who have experienced progression despite previous therapies or for whom no other satisfactory treatment options exist.
Zai Lab’s advancement in this application marks a crucial step in expanding treatment solutions for challenging oncological cases, enhancing the drug’s potential reach and impact in the patient community.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Zai Lab Ltd (ZLAB, Financial) is $54.42 with a high estimate of $74.00 and a low estimate of $36.10. The average target implies an upside of 88.69% from the current price of $28.84. More detailed estimate data can be found on the Zai Lab Ltd (ZLAB) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Zai Lab Ltd's (ZLAB, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Zai Lab Ltd (ZLAB, Financial) in one year is $68.51, suggesting a upside of 137.55% from the current price of $28.84. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Zai Lab Ltd (ZLAB) Summary page.
